Navigation Links
Cardium to Present at 10th Annual Biotech in Europe Investor Forum
Date:9/20/2010

SAN DIEGO, Sept. 20 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) announced today that Christopher J. Reinhard, Cardium's Chairman and Chief Executive Officer will present at the 10th Annual Biotech in Europe Investor Forum to be held September 29-30, 2010 at the Radisson Blu Hotel in Zurich.  Although this presentation will not be webcast, investors can access a replay of the Company's recent presentation at the Rodman & Renshaw 12th Annual Healthcare Investment Conference at http://www.wsw.com/webcast/rrshq18/cxm/ or at the Investors section of Cardium's website at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-calendar.  

(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

About Cardium

Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, partnering and other economic monetizations.  Cardium's current investment portfolio includes the Tissue Repair Company, Cardium Biologics, and the Company's in-house MedPodium lifestyle medicinals brand platform.  The Company's lead product candidates include: (1) Excellagen™ topical gel, for wound care management, which Cardium plans to market launch in the fourth quarter subject to pending FDA 510(k) clearance; and (2) Generx®, a DNA-based angiogenic cardiovascular biologic for patients in international markets with coronary artery disease.  In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities.  In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio.  News from Cardium is located at www.cardiumthx.com.

Copyright 2010 Cardium Therapeutics, Inc.  All rights reserved.

For Terms of Use Privacy Policy, please visit www.cardiumthx.com.

Cardium Therapeutics™ Generx® and MedPodium™ are trademarks of Cardium Therapeutics, Inc.

Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen™, Excellarate™, Osteorate™, Appexium™ and Linee™ are trademarks of Tissue Repair Company.


'/>"/>
SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cardium Regains Listing Compliance With NYSE Amex
2. Cardium to Present at MDB Capital Groups 2010 Bright Lights Conference
3. Cardiums Exchange Listing Compliance Plan Accepted by NYSE AMEX
4. Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments
5. Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds
6. Cardium Completes $6.0 Million Registered Direct Offering
7. Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors
8. Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications
9. Cardium Regains Listing Compliance with NYSE Amex
10. Cardiums InnerCool Therapies Business to Be Acquired By Royal Philips Electronics
11. Cardium Announces Conference Call and Webcast to Review Recent Developments and Future Plans for the Excellarate(TM) Clinical Development Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Three-Year Initiative Supports Next Generation of ... in Life-Changing Camp Experiences ... affect the lives of children born with rare diseases, as well ... ) is announcing a new initiative designed to positively affect the ... future of rare disease care. --> To mark the ...
(Date:2/8/2016)... Feb. 8, 2016 Should antibiotic bone cement ... products to prevent infection after standard total hip or ... at ECRI Institute have been fielding a lot lately. ... Your Bottom Line?" --> "Antibiotic ... --> While there isn,t a ...
(Date:2/8/2016)... ... 2016 , ... Thomas J. Todorow has joined the University ... Corporate Services and the Chief Financial Officer at The Children’s Hospital of Philadelphia ... Care Contracting, Supply Chain, and Investments. , Prior to joining CHOP and The ...
(Date:2/8/2016)... ... 2016 , ... Franz Inc. , an early innovator ... announced the availability of AllegroGraph 6, the leading Semantic Graph Database with certification ... Program (CCPT). AllegroGraph is the first Semantic Graph Database to be certified ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016 Technology Enhancements Accelerate ... an analysis of the digital and computed radiography markets ... , and Indonesia (TIM). ... and market size, as well as regional market drivers ... and discusses market penetration and market attractiveness, both for ...
(Date:2/1/2016)... NEW YORK , Feb. 1, 2016  Today, ... Heart Association (AHA) announced plans to develop a first ... cognitive computing power of IBM Watson. In the first ... disease, AHA, IBM (NYSE: IBM ), and Welltok ... metrics and health assessments with cognitive analytics, delivered on ...
(Date:1/25/2016)... BLUE BELL, Pa. , Jan. 25, 2016   Unisys ... facial recognition system at John F. Kennedy (JFK) International Airport, ... and Border Protection (CBP) identify imposters attempting to enter ... or do not belong to them. pilot testing ... rolled out initially at three terminals at JFK during January 2016. ...
Breaking Biology News(10 mins):